News Releases
Fibrocell Science CEO Rings the New York Stock Exchange Closing Bell
EXTON, Pa.–Fibrocell Science, Inc. (NYSE MKT : FCSC), an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications, announced today that Chief Executive Officer and Chairman David Pernock, will preside over the Closing Bell on Tuesday, June 4, 2013 at 4 p.m. Eastern Time at the NewRead more
Fibrocell Science Announces Approval of Common Stock Listing on NYSE MKT
EXTON, Pa.–Fibrocell Science, Inc. (OTC:FCSCD) announced today that its common stock has been approved for listing on the NYSE MKT. Trading is expected to commence on the NYSE MKT on Friday, May 17, 2013 under the ticker symbol “FCSC”. “The NYSE MKT listing is a significant corporate milestone for Fibrocell Science. The NYSE listing shouldRead more
Fibrocell Science Expands Potential Medical Applications for Azficel-T
Company Announces Initiation of Phase II Study for the Treatment of Restrictive Burn Scars May 02, 2013, EXTON, PA – Fibrocell Science, Inc. (OTC: FCSCD) announced today the initiation of a Phase II trial for azficel-T, an autologous fibroblast cellular product, for the treatment of restrictive burn scars (RBS). The Phase II double-blind, randomized, placebo-controlledRead more
Fibrocell Science Announces One-for-Twenty-Five Reverse Stock Split
Fibrocell has been cleared to submit listing application to the NYSE MKT Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on April 30, 2013 Action Expected to Facilitate Listing on NYSE MKT April 29, 2013, EXTON, PA – Fibrocell Science, Inc. (OTC BB: FCSC) announced today that it will implement a one-for-twenty-five reverseRead more
Fibrocell Science LAVIV® Recognized as 2013 Edison Awards’ Silver Winner
Earns Prestigious Honor for Innovation in Aesthetics April 26, 2013, EXTON, PA – Fibrocell Science, Inc. (OTC: FCSC) today announced that LAVIV® (azficel-T) was recognized as the Silver Winner in aesthetics of the science/medical category at the 2013 Edison Awards Ceremony and Gala in Chicago. LAVIV is the first and only autologous cellular product approved byRead more